Uncategorized
Patients treated with ranibizumab for wet AMD may be at risk of developing macular atrophy
WAIKOLOA, Hawaii — Patients who are treated with ranibizumab for neovascular AMD may be at risk for developing macular atrophy, according to a speaker here.“Is [macular atrophy] truly associated with VEGF inhibition or is this the natural disease progression? Other conditions in which we treat VEGF inhibition aggressively such as diabetic macular edema or retinal vein occlusion do not develop the macular atrophy we see in neovascular AMD,” Diana V. Do, MD, said here at Retina 2016.